417 Poster The therapeutic management of ductal carcinoma in-situ: a comparison of europe and the United States

2002 ◽  
Vol 64 ◽  
pp. S138
Keyword(s):  
United States ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
The United States ◽  
Therapeutic Management

Growing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States

2015 ◽  
Vol 22 (7) ◽  
pp. 2378-2386 ◽  
Author(s):  
Charles E. Rutter ◽  
Henry S. Park ◽  
Brigid K. Killelea ◽  
Suzanne B. Evans
Keyword(s):  
United States ◽  
Young Women ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
The United States

Increasing Rates of Contralateral Prophylactic Mastectomy Among Patients With Ductal Carcinoma In Situ

2009 ◽  
Vol 27 (9) ◽  
pp. 1362-1367 ◽  
Author(s):  
Todd M. Tuttle ◽  
Stephanie Jarosek ◽  
Elizabeth B. Habermann ◽  
Amanda Arrington ◽  
Anasooya Abraham ◽  
...  
Keyword(s):  
United States ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Prophylactic Mastectomy ◽  
Lobular Carcinoma ◽  
Contralateral Prophylactic Mastectomy ◽  
Breast Conserving Surgery ◽  
The United States

Purpose Some women with unilateral ductal carcinoma in situ (DCIS) undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the opposite breast. The use and trends of CPM for DCIS in the United States have not previously been reported. Methods We used the Surveillance, Epidemiology, and End Results database to analyze the initial treatment (within 6 months) of patients with unilateral DCIS diagnosed from 1998 through 2005. We determined the CPM rate as a proportion of all surgically treated patients and as a proportion of all patients who underwent mastectomy. We compared demographic and tumor variables in women with unilateral DCIS who underwent surgical treatment. Results We identified 51,030 patients with DCIS; 2,072 patients chose CPM. The CPM rate was 4.1% for all surgically treated patients and 13.5% for patients undergoing mastectomy. Among all surgically treated patients (including breast-conserving surgery), the CPM rate increased by 148% from 1998 (2.1%) to 2005 (5.2%). Among patients who underwent mastectomy to treat DCIS (excluding patients undergoing breast-conserving surgery), the CPM rate increased by 188% from 1998 (6.4%) to 2005 (18.4%). Young patient age, white race, recent year of diagnosis, and the presence of lobular carcinoma in situ were significantly associated with higher CPM rates among all surgically treated patients and all patients undergoing mastectomy. Large tumor size and higher grade were significantly associated with increased CPM rates among all surgically treated patients but lower CPM rates among patients undergoing mastectomy. Conclusion The use of CPM for DCIS in the United States markedly increased from 1998 through 2005.

scholarly journals Incidence of Ductal Carcinoma In Situ in the United States, 2000–2014

2019 ◽  
Vol 28 (8) ◽  
pp. 1316-1323 ◽  
Author(s):  
Marc D. Ryser ◽  
Laura H. Hendrix ◽  
Mathias Worni ◽  
Yiling Liu ◽  
Terry Hyslop ◽  
...  
Keyword(s):  
United States ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
The United States

Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States

2018 ◽  
Vol 18 (3) ◽  
pp. 220-228 ◽  
Author(s):  
William A. Stokes ◽  
Arya Amini ◽  
Matthew W. Jackson ◽  
S. Reed Plimpton ◽  
Nicole Kounalakis ◽  
...  
Keyword(s):  
United States ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
External Beam Radiotherapy ◽  
The United States ◽  
External Beam

Ductal Carcinoma In Situ: Challenges, Opportunities, and Uncharted Waters

2012 ◽  
pp. 40-44 ◽  
Author(s):  
Abigail W. Hoffman ◽  
Catherine Ibarra-Drendall ◽  
Virginia Espina ◽  
Lance Liotta ◽  
Victoria Seewaldt
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
The United States ◽  
Targeted Prevention ◽  
Breast Cancers ◽  
Increased Risk

Overview: Ductal carcinoma in situ (DCIS) is a heterogeneous group of diseases that differ in biology and clinical behavior. Until 1980, DCIS represented less than 1% of all breast cancer cases. With the increased utilization of mammography, DCIS now accounts for 15% to 25% of newly diagnosed breast cancer cases in the United States. Although our ability to detect DCIS has radically improved, our understanding of the pathophysiology and factors involved in its progression to invasive carcinoma is still poorly defined. In many patients, DCIS will never progress to invasive breast cancer and these women are overtreated. In contrast, some DCIS cases are clinically aggressive and the women may be undertreated. We are able to define some of the predictors of aggressive DCIS compared with DCIS of low malignant potential. However, our ability to risk-stratify DCIS is still in its infancy. Clinical risk factors that predict aggressive disease and increased risk of local recurrence include young age at diagnosis, large lesion size, high nuclear grade, comedo necrosis, and involved margins. Treatment factors such as wider surgical margins and radiation therapy reduce the risk of local recurrence. DCIS represents a key intermediate in the stepwise progression to malignancy, but not all aggressive breast cancers appear to have a DCIS intermediate, notably within triple-negative breast cancer. Ongoing studies of the genetic and epigenetic alterations in precancerous breast lesions (atypia and DCIS) as well as the breast microenvironment are important for developing effective early detection and individualized targeted prevention.

Sign in / Sign up

Export Citation Format

Share Document